Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

Tianjin Sunny Peak Biotechnology Co., Ltd., established on 2014-12-29, Business scope includes biotechnology development,Technical Services,technical consulting,technology transfer;Chemicals(Hazardous chemicals and precursor chemicals are excluded)Sales;Inspection technical service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Develops and manufactures pharmaceutical products

Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd., established on 2019-06-25, Business scope includes pharmaceuticals,medical instruments,Healthy food,Health Supplies,R&D of cosmetics,Production,Sales and technical consultation,technology development,technology transfer;Computer Technology and Software Development,Biotechnology,Research and development of biomedical engineering technology,Technical Services,technical consulting,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC.

Stemina Biomarker Discovery, Inc., a metabolomics company, focuses on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health. The company works on collaborative research projects and joint development agreements with strategic partners to develop drugs, identify targets, and discover molecular biomarkers for the diagnosis of diseases and customized treatment. It provides metabolomics and mass spectrometry services, as well as develops diagnostic biomarkers. The company's cell-based assays arise from the strategic convergence of technologies, such as human embryonic stem (hES) cells and metabolomics. It uses mass spectrometry to analyze the small molecules secreted by hES, heart, and neural cells in response to drugs, injury, or disease. Stemina Biomarker Discovery, Inc. was founded in 2006 and is based in Madison, Wisconsin.

Xi'an Kangfunuo Biotechnology Co., Ltd., established on 2020-04-17, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Technology Import and Export;Import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Nippon Sanso KK is a private company headquartered in Japan, with operations in CN. The firm supplies industrial gases such as oxygen, nitrogen and argon; manufactures air separation plants, space simulation chambers and equipment related to liquid helium; supplies synthetic air; supplies LP gas; manufactures stainless steel vacuum bottles.\n.

Mitsui Knowledge Industry Co., Ltd. is engaged in the provision of information and communications technology services. It operates through the following segments: Business Solutions, Platform Solutions, and Services. The Business Solutions segment deals with enterprise resource planning and development, maintenance, and operation of industry-based applications. The Platform Solutions segment provides environment infrastructure, server integration, and sale of infrastructure equipment and other network equipment. The Services segment offers application hosting, cloud, monitoring, and operation services. The company was founded on June 20, 1991 and is headquartered in Tokyo, Japan.